Effects of valsartan or amlodipine on endothelial function and oxidative stress after one year follow-up in patients with essential hypertension

Yoshitaka Hirooka, Yoshikuni Kimura, Yoji Sagara, Koji Ito, Kenji Sunagawa

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Endothelial function is impaired in hypertensive patients. Decreased nitric oxide production and increased oxidative stress are involved in this abnormality. The aim of the present study was to evaluate whether endothelial function and oxidative stress differ following long-term antihypertensive treatment with an angiotensin type 1 receptor blocker, valsartan, or a calcium channel blocker, amlodipine, in patients with essential hypertension. Hypertensive patients were treated with valsartan (80-160 mg/day) or amlodipine (5-10 mg/day) for one year (n = 9 for each). The baseline blood pressure was similar between groups, and the magnitude of the decreases in blood pressure did not differ during treatment at three months, six months, or one year. Endothelial function and oxidative stress markers were examined before and after treatment. Endothelial function, assessed by flow-mediated vasodilation, was significantly improved in hypertensive patients treated with valsartan (5.8 ± 1.2 to 10.7 ± 1.4 %, p < 0.01) but not in those treated with amlodipine. The percent increase in vasodilation induced by sublingual nitroglycerin did not differ between the two groups. As markers of oxidative stress, urinary excretion of 8-isoprostane and 8-hydroxy-2'-deoxyguanosine was significantly reduced in patients treated with valsartan, but not in those treated with amlodipine. These findings suggest that the treatment of hypertensive patients with valsartan for at least one year improves endothelial function in association with reduced oxidative stress. The improved endothelial function and reduced oxidative stress might be involved in the benefits of anti-hypertensive treatment beyond simply lowering blood pressure, although the effects of treatment with valsartan or amlodipine over a much longer period are unknown.

Original languageEnglish
Pages (from-to)267-276
Number of pages10
JournalClinical and Experimental Hypertension
Volume30
Issue number3-4
DOIs
Publication statusPublished - Apr 1 2008

Fingerprint

Valsartan
Amlodipine
Oxidative Stress
8-epi-prostaglandin F2alpha
Blood Pressure
Vasodilation
Antihypertensive Agents
Therapeutics
Angiotensin II Type 1 Receptor Blockers
Nitroglycerin
Calcium Channel Blockers
Valsartan Drug Combination Amlodipine
Essential Hypertension
Nitric Oxide

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Cite this

Effects of valsartan or amlodipine on endothelial function and oxidative stress after one year follow-up in patients with essential hypertension. / Hirooka, Yoshitaka; Kimura, Yoshikuni; Sagara, Yoji; Ito, Koji; Sunagawa, Kenji.

In: Clinical and Experimental Hypertension, Vol. 30, No. 3-4, 01.04.2008, p. 267-276.

Research output: Contribution to journalArticle

Hirooka, Yoshitaka ; Kimura, Yoshikuni ; Sagara, Yoji ; Ito, Koji ; Sunagawa, Kenji. / Effects of valsartan or amlodipine on endothelial function and oxidative stress after one year follow-up in patients with essential hypertension. In: Clinical and Experimental Hypertension. 2008 ; Vol. 30, No. 3-4. pp. 267-276.
@article{f6e011205052405bb4fa90724f36ea08,
title = "Effects of valsartan or amlodipine on endothelial function and oxidative stress after one year follow-up in patients with essential hypertension",
abstract = "Endothelial function is impaired in hypertensive patients. Decreased nitric oxide production and increased oxidative stress are involved in this abnormality. The aim of the present study was to evaluate whether endothelial function and oxidative stress differ following long-term antihypertensive treatment with an angiotensin type 1 receptor blocker, valsartan, or a calcium channel blocker, amlodipine, in patients with essential hypertension. Hypertensive patients were treated with valsartan (80-160 mg/day) or amlodipine (5-10 mg/day) for one year (n = 9 for each). The baseline blood pressure was similar between groups, and the magnitude of the decreases in blood pressure did not differ during treatment at three months, six months, or one year. Endothelial function and oxidative stress markers were examined before and after treatment. Endothelial function, assessed by flow-mediated vasodilation, was significantly improved in hypertensive patients treated with valsartan (5.8 ± 1.2 to 10.7 ± 1.4 {\%}, p < 0.01) but not in those treated with amlodipine. The percent increase in vasodilation induced by sublingual nitroglycerin did not differ between the two groups. As markers of oxidative stress, urinary excretion of 8-isoprostane and 8-hydroxy-2'-deoxyguanosine was significantly reduced in patients treated with valsartan, but not in those treated with amlodipine. These findings suggest that the treatment of hypertensive patients with valsartan for at least one year improves endothelial function in association with reduced oxidative stress. The improved endothelial function and reduced oxidative stress might be involved in the benefits of anti-hypertensive treatment beyond simply lowering blood pressure, although the effects of treatment with valsartan or amlodipine over a much longer period are unknown.",
author = "Yoshitaka Hirooka and Yoshikuni Kimura and Yoji Sagara and Koji Ito and Kenji Sunagawa",
year = "2008",
month = "4",
day = "1",
doi = "10.1080/10641960802071000",
language = "English",
volume = "30",
pages = "267--276",
journal = "Clinical and Experimental Hypertension",
issn = "1064-1963",
publisher = "Informa Healthcare",
number = "3-4",

}

TY - JOUR

T1 - Effects of valsartan or amlodipine on endothelial function and oxidative stress after one year follow-up in patients with essential hypertension

AU - Hirooka, Yoshitaka

AU - Kimura, Yoshikuni

AU - Sagara, Yoji

AU - Ito, Koji

AU - Sunagawa, Kenji

PY - 2008/4/1

Y1 - 2008/4/1

N2 - Endothelial function is impaired in hypertensive patients. Decreased nitric oxide production and increased oxidative stress are involved in this abnormality. The aim of the present study was to evaluate whether endothelial function and oxidative stress differ following long-term antihypertensive treatment with an angiotensin type 1 receptor blocker, valsartan, or a calcium channel blocker, amlodipine, in patients with essential hypertension. Hypertensive patients were treated with valsartan (80-160 mg/day) or amlodipine (5-10 mg/day) for one year (n = 9 for each). The baseline blood pressure was similar between groups, and the magnitude of the decreases in blood pressure did not differ during treatment at three months, six months, or one year. Endothelial function and oxidative stress markers were examined before and after treatment. Endothelial function, assessed by flow-mediated vasodilation, was significantly improved in hypertensive patients treated with valsartan (5.8 ± 1.2 to 10.7 ± 1.4 %, p < 0.01) but not in those treated with amlodipine. The percent increase in vasodilation induced by sublingual nitroglycerin did not differ between the two groups. As markers of oxidative stress, urinary excretion of 8-isoprostane and 8-hydroxy-2'-deoxyguanosine was significantly reduced in patients treated with valsartan, but not in those treated with amlodipine. These findings suggest that the treatment of hypertensive patients with valsartan for at least one year improves endothelial function in association with reduced oxidative stress. The improved endothelial function and reduced oxidative stress might be involved in the benefits of anti-hypertensive treatment beyond simply lowering blood pressure, although the effects of treatment with valsartan or amlodipine over a much longer period are unknown.

AB - Endothelial function is impaired in hypertensive patients. Decreased nitric oxide production and increased oxidative stress are involved in this abnormality. The aim of the present study was to evaluate whether endothelial function and oxidative stress differ following long-term antihypertensive treatment with an angiotensin type 1 receptor blocker, valsartan, or a calcium channel blocker, amlodipine, in patients with essential hypertension. Hypertensive patients were treated with valsartan (80-160 mg/day) or amlodipine (5-10 mg/day) for one year (n = 9 for each). The baseline blood pressure was similar between groups, and the magnitude of the decreases in blood pressure did not differ during treatment at three months, six months, or one year. Endothelial function and oxidative stress markers were examined before and after treatment. Endothelial function, assessed by flow-mediated vasodilation, was significantly improved in hypertensive patients treated with valsartan (5.8 ± 1.2 to 10.7 ± 1.4 %, p < 0.01) but not in those treated with amlodipine. The percent increase in vasodilation induced by sublingual nitroglycerin did not differ between the two groups. As markers of oxidative stress, urinary excretion of 8-isoprostane and 8-hydroxy-2'-deoxyguanosine was significantly reduced in patients treated with valsartan, but not in those treated with amlodipine. These findings suggest that the treatment of hypertensive patients with valsartan for at least one year improves endothelial function in association with reduced oxidative stress. The improved endothelial function and reduced oxidative stress might be involved in the benefits of anti-hypertensive treatment beyond simply lowering blood pressure, although the effects of treatment with valsartan or amlodipine over a much longer period are unknown.

UR - http://www.scopus.com/inward/record.url?scp=42349105620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42349105620&partnerID=8YFLogxK

U2 - 10.1080/10641960802071000

DO - 10.1080/10641960802071000

M3 - Article

C2 - 18425706

AN - SCOPUS:42349105620

VL - 30

SP - 267

EP - 276

JO - Clinical and Experimental Hypertension

JF - Clinical and Experimental Hypertension

SN - 1064-1963

IS - 3-4

ER -